Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Flu-ID 15μg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Inactivated Split-Virion Influenza Vaccine for Intradermal Route |
| 2 | ACTIVE_COMPARATOR | Inactivated adjuvanted Influenza Vaccine for Intramuscular Route |
| Name | Type | Description |
|---|---|---|
| Flu-ID 15μg | BIOLOGICAL | Inactivated Split-Virion Influenza Vaccine for Intradermal Route |
| Inactivated adjuvanted Influenza Vaccine | BIOLOGICAL | Inactivated adjuvanted Influenza Vaccine for Intramuscular Route |
Inclusion Criteria: * Aged 65 years or older on the day of inclusion Exclusion Criteria: * Febrile illness (oral temperature ≥37.5°C) on the day of inclusion * Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination * Unstable chronic illness * Congenital or acquired immu...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
Flu-ID 15μg is an investigational vaccine being developed for the prevention of influenza. It is a monoclonal antibody-based product intended to provide immunity against the flu virus. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
Flu-ID 15μg is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and immunogenicity of this influenza vaccine candidate.
Flu-ID 15μg is in Phase 3 clinical development. It is an investigational vaccine and has not yet received regulatory approval. The Phase 3 trial has been completed, and the results will inform potential future regulatory submissions.
Flu-ID 15μg has been studied in one completed Phase 3 clinical trial with the identifier NCT00554333. This trial compared the immunogenicity and safety of Flu-ID 15μg against a Flu-IM vaccine in 795 participants aged 65 years and older in Belgium and France.
No, Flu-ID 15μg is not the same as Flu-IM. Flu-ID 15μg is an investigational vaccine being developed by Sanofi, while Flu-IM is a comparator vaccine used in the clinical trial. The trial was designed to compare the immune response and safety of the two vaccines.